Loading...
The progestin drospirenone has spironolactone-like potassium-sparing activity; therefore, prescribing instructions for EE/DRSP (ethinyl estradiol [0.03 mg] plus drospirenone [3 mg]) oral contraceptives (OCs) warn against their use in women with conditions that predispose them to hyperkalemia. In an FDA-requested, manufacturer-supported study, researchers used a large electronic database to compare hyperkalemia incidence in 22,429 women who initiated EE/DRSP OCs with that in 44,858 women who initiated other OCs during a 3-year period. Medical histories covering the 6 months before OC initiation, as well as hyperkalemia-related outcomes after OC initiation (electrolyte disturbances, arrhythmia, syncope, myocardial infarction, dialysis, and de…